Skip to content

Study · Animal study (in vivo) · rat · 2005

3 results

Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats.

Gedulin BR, Smith P, Prickett KS, Tryon M, Barnhill S, Reynolds J, Nielsen LL, Parkes DG, Young AA

Diabetologia25 May 2005Cited by 56 (Europe PMC)

PMID15915337 (opens in a new tab)DOI10.1007/s00125-005-1795-2 (opens in a new tab)PepBankPUB-15915337
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic fatty Zucker rats, exenatide-LAR prevented HbA1c deterioration dose-proportionally, with median effective dose 74 microg per rat and concentration 52 pmol/l.

    In plain wordsIn rats with diabetes, exenatide-LAR prevented worsening blood sugar control compared with controls.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c deterioration
    Study

    ratn: not reported in source

    Diabetic fatty Zucker rats
    Comparator
    Control
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1-9000 mug single injection · subcutaneous · 28 daysAs given in this study (rat).

    Measurements

    Median effective dose
    74 microg
    per rat
    Median effective concentration
    52 pmol/l
    HbA1c deterioration

    Source sentences

    Summary
    In contrast to the progressive 3.22+/-0.42% increase in HbA1c in control ZDF rats observed over 28 days, single exenatide-LAR injections dose-proportionally prevented such glycaemic deterioration (median effective dose 74 microg+/-0.1 log per rat; median effective concentration 52 pmol/l+/-0.06 log).
    1 context sentence
    Summary · context
    Single subcutaneous injections of a poly-lactide-glycolide microsphere suspension (3% peptide) containing 0, 1, 10, 100, 1,000, 3,000 or 9,000 mug exenatide were administered to 9-week-old ZDF rats with matched initial HbA1c values (n=7 rats/group).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic fatty Zucker rats, lower exenatide-LAR doses increased beta-cell responses to glucose challenge after treatment.

    In plain wordsIn rats with diabetes, lower exenatide-LAR doses increased insulin-cell responses to glucose compared with controls.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBeta-cell response to glucose
    Study

    ratn: not reported in source

    Diabetic fatty Zucker rats
    Comparator
    Control
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1-9000 mug single injection · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Hyperinsulinaemic-euglycaemic clamp procedures incorporating an intraclamp glucose challenge performed 28 days after treatment revealed increases in beta cell response to the glucose challenge at lower exenatide-LAR doses, and up to a 2.1-fold increase in insulin sensitivity at higher exenatide-LAR doses.
    1 context sentence
    Summary · context
    Single subcutaneous injections of a poly-lactide-glycolide microsphere suspension (3% peptide) containing 0, 1, 10, 100, 1,000, 3,000 or 9,000 mug exenatide were administered to 9-week-old ZDF rats with matched initial HbA1c values (n=7 rats/group).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic fatty Zucker rats, higher exenatide-LAR doses increased insulin sensitivity up to 2.1-fold.

    In plain wordsIn rats with diabetes, higher exenatide-LAR doses increased insulin sensitivity compared with controls.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulin sensitivity
    Study

    ratn: not reported in source

    Diabetic fatty Zucker rats
    Comparator
    Control
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1-9000 mug single injection · subcutaneous · 28 daysAs given in this study (rat).

    Source sentences

    Summary
    Hyperinsulinaemic-euglycaemic clamp procedures incorporating an intraclamp glucose challenge performed 28 days after treatment revealed increases in beta cell response to the glucose challenge at lower exenatide-LAR doses, and up to a 2.1-fold increase in insulin sensitivity at higher exenatide-LAR doses.
    1 context sentence
    Summary · context
    Single subcutaneous injections of a poly-lactide-glycolide microsphere suspension (3% peptide) containing 0, 1, 10, 100, 1,000, 3,000 or 9,000 mug exenatide were administered to 9-week-old ZDF rats with matched initial HbA1c values (n=7 rats/group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.